Biogen | BIIB - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 12.54B 474M 2026-03
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
ALKERMES USD 338.34M 72.51M 2025-12
Amgen USD 6.48B 307M 2025-09
Bayer EUR 5.35B 1.02B 2025-09
Biogen USD 1.82B 169.5M 2026-03
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Eli Lilly USD 14.59B 1.48B 2025-09
Esperion Therapeutics USD 140.59M 94.57M 2025-12
Gilead Sciences USD 6.31B 106M 2025-12
Incyte USD 1.17B 217.51M 2026-03
Merck USD 13.42B 431M 2025-09
Moderna USD 226M 583M 2025-12
Neurocrine Biosciences USD 787.9M 7M 2025-12
Novartis USD 10.25B 570M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
PTC Therapeutics USD 148.38M 39.31M 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 2.94B 363.7M 2026-03
Sangamo BioSciences -2.39M 1.09M 2024-06
Sanofi EUR 8.45B 1.31B 2025-12
Sanofi EUR 8.45B 3.02B 2025-12
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
Teva Pharmaceutical Industries USD 2.11B 547M 2026-03
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
United Therapeutics USD 315.5M 286.6M 2025-12
Vertex Pharmaceuticals USD 2.72B 62.4M 2025-12